ES2044087T3 - Un metodo para preparar una composicion de 13,14-dihidro-15-cetoprostaglandina estabilizada. - Google Patents

Un metodo para preparar una composicion de 13,14-dihidro-15-cetoprostaglandina estabilizada.

Info

Publication number
ES2044087T3
ES2044087T3 ES89301888T ES89301888T ES2044087T3 ES 2044087 T3 ES2044087 T3 ES 2044087T3 ES 89301888 T ES89301888 T ES 89301888T ES 89301888 T ES89301888 T ES 89301888T ES 2044087 T3 ES2044087 T3 ES 2044087T3
Authority
ES
Spain
Prior art keywords
dihydro
cetoprostaglandine
stabilized
preparing
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89301888T
Other languages
English (en)
Spanish (es)
Inventor
Ryuji Ueno
Sachiko Kuno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ueno Seiyaku Oyo Kenkyujo KK
Original Assignee
Ueno Seiyaku Oyo Kenkyujo KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ueno Seiyaku Oyo Kenkyujo KK filed Critical Ueno Seiyaku Oyo Kenkyujo KK
Application granted granted Critical
Publication of ES2044087T3 publication Critical patent/ES2044087T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES89301888T 1988-02-26 1989-02-24 Un metodo para preparar una composicion de 13,14-dihidro-15-cetoprostaglandina estabilizada. Expired - Lifetime ES2044087T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP63045622A JP2597629B2 (ja) 1988-02-26 1988-02-26 13,14−ジヒドロ−15−ケトプロスタグランジン類の安定化

Publications (1)

Publication Number Publication Date
ES2044087T3 true ES2044087T3 (es) 1994-01-01

Family

ID=12724473

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89301888T Expired - Lifetime ES2044087T3 (es) 1988-02-26 1989-02-24 Un metodo para preparar una composicion de 13,14-dihidro-15-cetoprostaglandina estabilizada.

Country Status (13)

Country Link
EP (1) EP0330511B1 (Direct)
JP (1) JP2597629B2 (Direct)
KR (1) KR970005170B1 (Direct)
AT (1) ATE79260T1 (Direct)
AU (1) AU612791B2 (Direct)
CA (1) CA1314483C (Direct)
DE (1) DE68902401T2 (Direct)
ES (1) ES2044087T3 (Direct)
GB (1) GB2216004A (Direct)
GR (1) GR3005933T3 (Direct)
NZ (1) NZ228111A (Direct)
OA (1) OA09236A (Direct)
ZA (1) ZA891410B (Direct)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166178B1 (en) * 1987-09-18 1998-07-21 R Tech Ueno Ltd Ocular hypotensive agents
ATE82499T1 (de) * 1987-09-18 1992-12-15 R Tech Ueno Ltd Okulare hypotensivagenzien.
US5212200A (en) * 1987-09-18 1993-05-18 R-Tech Ueno, Ltd. Ocular hypotensive agents
US5236907A (en) * 1988-10-01 1993-08-17 R-Tech Ueno Ltd. Ocular hypotensive agents
US6420422B1 (en) 1987-09-18 2002-07-16 Sucampo Pharmaceuticals, Inc. Ocular hypotensive agents
US5565492A (en) * 1988-07-18 1996-10-15 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
EP1225168B8 (en) * 1988-09-06 2015-03-18 Pfizer Health AB Prostaglandin-F-2 alpha derivative for the treatment of glaucoma or ocular hypertension
US5194429A (en) * 1988-10-01 1993-03-16 K.K. Ueno Seiyaku Oyo Kenkyujo Ocular hypotensive agents
DE68928551T2 (de) * 1988-10-01 1998-04-23 Ueno Seiyaku Oyo Kenkyujo Kk Oculare hypotensive Mittel
DE69019431T2 (de) * 1989-07-27 1995-09-14 Ueno Seiyaku Oyo Kenkyujo Kk Verwendung von 15-Keto-Prostansäure-Derivaten zur Herstellung eines Medikaments für die Verbesserung der Ausscheidung des Kaliumions.
US5234954A (en) * 1989-07-27 1993-08-10 K.K. Ueno Seiyaku Oyo Kenkyujo Treatment of hyperlipidemia with 15-keto-prostaglandin compounds
DE69018903T2 (de) * 1989-08-09 1995-08-24 Ueno Seiyaku Oyo Kenkyujo Kk Verwendung von Prostansäurederivaten zur Herstellung von Arzneimitteln zur Verbesserung der Ausscheidung von Nichtprotein in die Därme.
CA2027814C (en) * 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
CA2030344C (en) * 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
US5254588A (en) * 1989-11-22 1993-10-19 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of pulmonary dysfunction with 15-ketoprostaglandin compounds
CA2030346C (en) * 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
US5256696A (en) * 1989-11-22 1993-10-26 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of cardiac dysfunction with 15-ketoprostaglandin compounds
CA2031469A1 (en) * 1989-12-28 1991-06-29 Larry A. Wheeler Use of inclusion complexes of prostaglandins with cyclodextrins in the treatment of ocular hypertension
CA2039420C (en) * 1990-04-04 1996-12-10 Ryuji Ueno Treatment of cataract with 15-keto-prostaglandin compounds
CA2046069C (en) * 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
DE69213057T2 (de) * 1991-03-14 1997-01-09 Ueno Seiyaku Oyo Kenkyujo Kk Stimulierung von Wundheilung mit 15-Keto-prostaglandinverbindungen
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US6184250B1 (en) 1993-08-03 2001-02-06 Alcon Laboratories, Inc. Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension
US5698733A (en) * 1994-09-30 1997-12-16 Alcon Laboratories, Inc. Use of 9-deoxy prostaglandin derivatives to treat glaucoma
US5807892A (en) * 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AU7672096A (en) 1995-06-07 1998-06-03 Alcon Laboratories, Inc. Conformationally rigid aryl- or heteroaryl prostaglandins for use in glaucoma therapy
US6096783A (en) * 1998-12-15 2000-08-01 Alcon Laboratories, Inc. Cyclobutane prostaglandin analogues as ocular hypotensive agents
US6211226B1 (en) 1998-12-17 2001-04-03 Alcon Laboratories, Inc. 11-Aza prostaglandins for the treatment of glaucoma and ocular hypertension
ES2379652T3 (es) 2002-10-23 2012-04-30 Sucampo Ag Compuestos de prostaglandina para el tratamiento de obesidad
DE602004023106D1 (de) * 2003-11-07 2009-10-22 Senju Pharma Co Pharmazeutische zusammensetzung mit prostaglandin
EP1985298A1 (en) 2007-04-24 2008-10-29 Azad Pharma AG Ophtalmic oil-in-water emulsions containing prostaglandins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5910525A (ja) * 1982-06-21 1984-01-20 Teisan Seiyaku Kk プロスタグランジンeの安定化組成物
JPH0819004B2 (ja) * 1986-12-26 1996-02-28 日清製粉株式会社 徐放性医薬製剤
CA1323364C (en) 1987-01-28 1993-10-19 Ryuzo Ueno Prostaglandins e and anti ulcer agents containing same
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
CA1324129C (en) 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
ES2038289T3 (es) 1987-05-15 1993-07-16 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Utilizacion de 15-ceto-pges para la fabricacion de un medicamento para aumentar la temperatura corporal.
ATE82499T1 (de) 1987-09-18 1992-12-15 R Tech Ueno Ltd Okulare hypotensivagenzien.

Also Published As

Publication number Publication date
GB2216004A (en) 1989-10-04
OA09236A (en) 1992-06-30
ZA891410B (en) 1989-11-29
AU3029889A (en) 1989-08-31
KR970005170B1 (en) 1997-04-14
EP0330511A2 (en) 1989-08-30
NZ228111A (en) 1991-02-26
GB8904232D0 (en) 1989-04-12
KR890012654A (ko) 1989-09-18
EP0330511B1 (en) 1992-08-12
AU612791B2 (en) 1991-07-18
EP0330511A3 (en) 1989-10-18
JPH01221317A (ja) 1989-09-04
CA1314483C (en) 1993-03-16
DE68902401T2 (de) 1992-12-10
GR3005933T3 (Direct) 1993-06-07
DE68902401D1 (de) 1992-09-17
JP2597629B2 (ja) 1997-04-09
ATE79260T1 (de) 1992-08-15

Similar Documents

Publication Publication Date Title
ES2044087T3 (es) Un metodo para preparar una composicion de 13,14-dihidro-15-cetoprostaglandina estabilizada.
ES2163511T3 (es) Preparacion farmaceutica conteniendo glucagon.
ES2068179T3 (es) Benzo(5,6)-ciclohepta-piridinas, composiciones y metodo de uso.
LU88750I2 (fr) VENLAFAXINE et ses dérivés pharmaceutiquement acceptables
MY107158A (en) 3-arylcarbonyl; -1h-indoles useful as therapeutic agents.
LU90951I2 (fr) Eurifel rcp felv et ses dérivés pharmaceutiquement acceptables
GR890100838A (el) Νέα ?εραπευτικώς δραστική ένωσις και μέ?οδος για την παραγωγή της.
GT199700009A (es) Terapia combinada para la osteoporosis.
NO855048L (no) Fremgangsmaate for fremstilling av et stabilisert nicorandil-preparat.
NO894712D0 (no) Organopolysiloksan-blanding for dannelse av en sperrefilm.
MX9207394A (es) Esteroides de 17-espirofuran-3'-ilideno.
AR002157A1 (es) Uso de una dosis inmunizante eficaz de esporozoitos o merozoitos de eimeria vivos, o una mezcla de los mismos
DE69828043D1 (de) Fluoridfreie zahnremineralisierung
ES540758A0 (es) Un procedimiento para la preparacion de una composicion blanqueante de poroxido de hidrogeno.
MX9202935A (es) Derivados de 2,3-dihidro-1h-indeno y composicion farmaceutica que los contiene.
MY104979A (en) [ 5(6)(ih-azole-1-ylmethyl) benzimidazole] carbamates.
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
ES2038163T3 (es) Procedimiento para preparar 1,3-dioxolanos trisustituidos en 2,4,4 y tetrasustituidos en 2,2,4,4.
FI852743A7 (fi) Asetyleenisiä fenoksipropanolijohdannaisia ja farmaseuttisia koostumuksia hypertoniahoitamiseksi.
PT81933B (pt) Processo para a preparacao de composicoes aperfeicoadas anti-inflamatorias contendo piroxicamo e inositol
ES541436A0 (es) Procedimiento para preparar un agente farmaceutico que con- tiene un inhibidor de la enzima convertidora de angiotensina
IT8049526A0 (it) Composizione per la profilassi e terapia di epatite a base di un composto sesquiterpenico
ES556785A0 (es) Un procedimiento para preparar una composicion farmaceutica de una linfocina (lk2).
IT1229178B (it) Procedimento per l'ottenimento di una miscela di ribonucleotidi.
SE8800461D0 (sv) Farmaceutisk komposition

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 330511

Country of ref document: ES